Biocon Biologics Reaches Milestone with Encouraging Phase 3 Results for Ustekinumab Biosimilar

Unknown Apr 02, 2026 1,300 Views

March 7, 2025: Biocon Biologics has revealed encouraging findings in its Phase 3 clinical trial for Yesintek, a ustekinumab biosimilar, prescribed in the treatment of chronic plaque psoriasis. The trial proved high efficacy and safety profiles that were similar to the reference product, represent...

Stay Ahead – Explore Now! No Scheduled Delhi Power Cut in BRPL Areas on Monday, June 15